Dossier assessment
Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
First assessment of the established drug market: advantage for sitagliptin
Hints of added benefit / no conclusive data for other gliptins / no long-term studies
Project details
- Project no.
- A13-12
- Commission
- Commission awarded on 19.03.2013 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Saxagliptin/metformin - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Saxagliptin - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed